A prodrug is a strategic innovation in biopharmaceutics designed to enhance the absorption, distribution, and delivery of therapeutic agents within the human body. This ingenious approach involves the administration of an inactive precursor that undergoes a biotransformation to the active drug form, either enzymatically or non-enzymatically, after administration.
In biopharmaceutics, prodrugs address challenges such as poor solubility, stability, or limited bioavailability of certain drugs. By converting the active compound into a prodrug, these limitations can be overcome, leading to improved therapeutic outcomes. Prodrugs also allow for targeted drug delivery, minimizing potential side effects and enhancing patient compliance.
The versatility of prodrugs spans various drug classes, including analgesics, antivirals, and anticancer agents. This approach exemplifies the continual evolution of pharmaceutical science in optimizing drug performance and patient well-being. As a key player in the realm of biopharmaceutics, prodrugs pave the way for more efficient and precise drug delivery strategies in the field of medicine.
Vladlen Slepak
University of Miami School of Medicine, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Consolato M Sergi
University of Alberta, Canada
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Lan Wang
Paretor LLC, United States
Maria Cristina Gamberini
University of Modena and Reggio Emilia, Italy
Lucas Amaral Machado
University of Sao Paulo State – UNESP, Brazil
Saad Tayyab
UCSI University, Malaysia
Anil Pareek
Anand Pharmacy College, IndiaSubmit your abstract Today
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami School of Medicine, United States
Title : Tailored cellular environments to enable drug design
Lan Wang, Paretor LLC, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, InMedStar and Biona, Russian Federation
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Application of quality by design for pulmonary liposomes: Preliminary study to nano in-microparticle
Lucas Amaral Machado, University of Sao Paulo State – UNESP, Brazil
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil